Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1675 1676
This examiner grants 61% of resolved cases
Sergio Coffa works in Tech Center 1600 and Art Unit 1654. He has 748 resolved cases and an allowance rate of 61.1 percent. This rate indicates the likelihood of success for applicants. The median days to allowance is 1066, which is the timeframe for this tech center.
The interview lift is 32.5 percent. This lift suggests that interviews are an effective way to increase the 61.1 percent allowance rate. In Tech Center 1600, the 32.5 percent lift can help clarify technical issues and move cases toward a final allowance.
The 748 resolved cases provide a data set for evaluating this examiner. The 61.1 percent allowance rate and the 1066 days median to allowance offer expectations for practitioners. Utilizing the 32.5 percent interview lift may be a tactic for those seeking to improve their outcomes in Art Unit 1654. The combination of these metrics defines the current prosecution landscape for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18257237 | DIPHENHYDRAMINE AND LACTOFERRIN FOR PREVENTION AND TREATMENT OF COVID-19 | Final Rejection | University of Florida Research Foundation, Incorporated |
| 18644750 | CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES | Non-Final OA | Ohio State Innovation Foundation |
| 18582271 | p53 VARIANT WITH IMPROVED LIQUID-LIQUID PHASE SEPARATION ABILITY AND ACTIVITY AND USE THEREOF | Non-Final OA | Zhejiang University |
| 18257483 | COMPOSITIONS AND METHODS FOR MODULATING MYC EXPRESSION | Final Rejection | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18294021 | NORA INHIBITORS AND METHODS OF USE | Non-Final OA | NEW YORK UNIVERSITY |
| 18836118 | PEPTIDE HAVING ANTIBACTERIAL, ANTI-INFLAMMATORY OR TISSUE REGENERATION ABILITY AND USE THEREOF | Non-Final OA | Seoul National University R&DB Foundation |
| 18553437 | ANGIOGENESIS INHIBITING PEPTIDE AND USE THEREOF | Non-Final OA | SEOUL NATIONAL UNIVERSITY HOSPITAL |
| 17839820 | TARGETING G3BP PROTEINS TO ACCELERATE NERVE REGENERATION | Non-Final OA | University of South Carolina |
| 17518047 | METHOD FOR TREATING OPIOID USE DISORDER | Final Rejection | The United States Government as represented by the Department of Veterans Affairs |
| 17778138 | PENTAPEPTIDE AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 17675910 | PEPTIDES FOR THE TREATMENT OF RENAL DISORDERS | Non-Final OA | RAMOT AT TEL-AVIV UNIVERSITY LTD. |
| 18281189 | GAL3BP POLYPEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER AND DETERMINING TREATMENT RESPONSIVENESS | Final Rejection | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18580752 | PEPTIDE, COMPOSITION FOR RECOVERING RARE EARTH ELEMENTS COMPRISING SAME, AND RECOVERY METHOD | Non-Final OA | GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY |
| 18316988 | TREATMENT OF PATIENTS WITH SEVERE VON WILLEBRAND DISEASE UNDERGOING ELECTIVE SURGERY BY ADMINISTRATION OF RECOMBINANT VWF | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 17264720 | FORMULATIONS FOR IMPROVED STABILITY OF RECOMBINANT HUMAN PARATHYROID HORMONE | Final Rejection | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18724255 | PEPTIDE HAVING ACTIVITY OF IMPROVING STATE OF SKIN, AND USE THEREOF | Non-Final OA | CAREGEN CO., LTD. |
| 18008771 | DOCK TAG SYSTEM | Non-Final OA | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18703101 | RECOMBINANT POLYPEPTIDE FOR DISRUPTING INTERACTION OF EAG2 AND KVß2 AND THERAPEUTIC APPLICATIONS THEREOF IN CANCER TREATMENT | Final Rejection | The Hospital for Sick Children |
| 18794181 | AMNIOTIC MEMBRANE POWDER AND ITS USE IN WOUND HEALING AND TISSUE ENGINEERING CONSTRUCTS | Non-Final OA | WAKE FOREST UNIVERSITY HEALTH SCIENCES |
| 16611172 | Use of a Vaccine Targeting a Cryptic Tert Epitope, for Treating Lung Cancer in a HLA-A*0201-Positive Never-Smoker or Light-Former Smoker Patient | Final Rejection | KRIPTIC PHARMACEUTICALS LIMITED |
| 18705888 | ANTIBACTERIAL PEPTIDE | Non-Final OA | CURENC AB |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy